Aytu BioScience Inc (AYTU) Gets a Buy Rating from Northland Securities

By Jason Carr

In a report released today, Carl Byrnes from Northland Securities reiterated a Buy rating on Aytu BioScience Inc (AYTUResearch Report), with a price target of $10. The company’s shares closed yesterday at $1.59.

Byrnes said:

“We perceive the co-promotion agreement positively as significantly enhances direct selling of Natesto while placing a higher promotional focus on urologists and endocrinologists. Pre-open, Aytu BioScience announced that it amended its agreement with Acerus Pharmaceuticals, wherein Natesto (testosterone nasal gel spray for the treatment of Low-T) will be co-promoted with Acerus Pharamceuticals. Under the terms of the amended agreement and upon closing, Acerus Pharmaceuticals will launch a complementary US commercial team of at least 25 US-based specialty sales reps that will market Natesto directly to urologists and endocrinologists. This will nearly double the size of the Natesto field salesforce.”

According to TipRanks.com, Byrnes has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.7% and a 21.7% success rate. Byrnes covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals Inc, Opiant Pharmaceuticals Inc, and Adamas Pharmaceuticals.

Aytu BioScience Inc has an analyst consensus of Moderate Buy, with a price target consensus of $10.

See today’s analyst top recommended stocks >>

Based on Aytu BioScience Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.5 million. In comparison, last year the company had a net profit of $547.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aytu BioScience, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of novel products for urology. It operates through the Aytu, and Aytu Women’s Health segments. The Aytu segment consists of core male urology products.